Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 4Post-market surveillance

1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completed

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

NCT03369301

terminated

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

NCT03656640

completedphase_4

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

NCT02180763

Clinical Trials (3)

Showing 3 of 3 trials

NCT03369301

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Completed

NCT03656640

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Terminated

NCT02180763Phase 4

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3